Illustration: Brendan Lynch/Axios
Immunology and cancer biotech Electra Therapeutics saw shares close at $13.25 on Friday in its public market debut.
The big picture: Electra joins 21 other biotechs that went public this year, up from just 11 last year, per BioPharma Dive data.
